VKTX Viking Therapeutics, Inc.

1.29
+0.01  (1%)
Previous Close 1.28
Open 1.26
Price To book 4.06
Market Cap 30.86M
Shares 23,925,000
Volume 30,328
Short Ratio 1.72
Av. Daily Volume 109,316

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2017.
VK2809
Hypercholesterolemia
Phase 2 data due late summer 2017.
VK5211
Acute Hip Fracture

Latest News

  1. VKTX: Multiple Data Readouts Ahead in 2017
  2. Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
  3. Viking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017
  4. Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference
  5. Viking Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
  6. Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2016 After Market Close on March 21, 2017
  7. Viking Therapeutics to Present at Upcoming Investor Conferences
  8. VKTX: Successful Preclinical Data for VK2809 in Glycogen Storage Disease 1a
  9. Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
  10. Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
  11. Viking Therapeutics to Present at 2017 BIO CEO & Investor Conference
  12. Viking Therapeutics Announces Senior Level Appointments to Management Team
  13. Viking Therapeutics to Present at Biotech Showcase 2017
  14. Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
  15. VKTX: Additional Data Show Promise of VK2809 in Lipid Disorders…
  16. 7 Stocks Under $10 That Could Make You a Lot of Money
  17. VKTX: Encouraging Preclinical Data for VK0214 in Mouse Model of X-ALD
  18. VKTX: Data From Phase 2 Studies of VK2809 for Hypercholersterolemia and VK5211 for Hip Fracture to be Reported in 2Q17
  19. Here’s Why Investors Are Watching Caterpillar, Sensata Technologies & Three Other Stocks
  20. Viking Therapeutics Gets Positive Top-Line Results From Proof-Of-Concept Trial Of VK0214